Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

More info
Skip Navigation
Back to search results

A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response DDR gene alterations

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03609216

Study #:
STUDY00145378

Start Date:
Apr 30, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03609216

View Complete Trial Details & Eligibility at ClinicalTrials.gov

To request an appointment, call 844-323-1227.